Hypersensitivity Reactions to Abacavir

Español (soon!) - July 4, 2008

CMEonHIV.com is dedicated to providing online CME presentations (slides with voiceover) on HIV/AIDS for healthcare professionals given by local and international experts to keep you up-to-date on the ongoing developments in the field.

Conference

"Hypersensitivity Reactions to Abacavir"
Dr. Simon Mallal (biography)
English - 2004-07-21 - 36 minutes

(39 slides)

Summary :
In this presentation, Dr. Simon Mallal examines hypersentivity reactions (HSR) to abacavir and discusses the emerging importance of genetic screening to susceptibility to abacavir HSR.

Dr. Mallal presents evidence in the clinical literature for suspecting a genetic predisposition. The clinical manifestations of abacavir HSR as well as its prevalence clinical trials and certain populations are discussed. The treatment of HSR is also reviewed.

Dr. Mallal presents his own research and other evidence from the literature for a benefit of screening HIV patients in certain populations for HLA-B*5701 alone and in conjuction with testing for Hsp70 hom ‘C’.

Dr. Mallal concludes his talk by proposing an immunological mechanism for HSR to abacavir based, in part, on his own data and on functional studies of the role of certain haplotypes in abacavir HSR.

Copyright © 2004 E-MedHosting.com Inc

Learning objectives :
After viewing this presentation, participants will be able to discuss:
• The epidemiology of abacavir hypersensitivity reactions (HSR)
• The clinical manifestations of abacavir HSR
• The management of HSR
• The evidence in the literature for the value of genetic screening for abacavir HSR susceptibility
• The patient populations to which the data cannot reasonably be extrapolated at the present time

Bibliographic references :
Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg. 1996 Dec;15(4):217-27.

deShazo RD, Kemp SF. Allergic reactions to drugs and biologic agents. JAMA. 1997 Dec 10;278(22):1895-906.

Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol. 1998 Sep;11(9):969-88.

Pohl LR 1988. Ann Rev Oharmacol Toxicol 28 : 267
Pohl LR, Satoh H, Christ DD, Kenna JG. The immunologic and metabolic basis of drug hypersensitivities. Annu Rev Pharmacol Toxicol. 1988;28:367-87.

Cutrell A et al. 1st IAS conference on HIV Pathogenesis and Treatment. 8-11 July 2001. Ab527.

Hetherington S, McGuirk S, Powell G, Cutrell A, Naderer O, Spreen B, Lafon S, Pearce G, Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001 Oct;23(10):1603-14.

Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother. 2001 Oct;35(10):1291-2.

Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology. 2001 Feb 2;158(1-2):11-23.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002 Mar 2;359(9308):727-32.

Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002 Mar 30;359(9312):1121-2.

Dawkins RL, Christiansen FT, Kay PH, Garlepp M, McCluskey J, Hollingsworth PN, Zilko PJ. Disease associations with complotypes, supratypes and haplotypes. Immunol Rev. 1983;70:1-22.

Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002 Nov 8;16(16):2223-5.

Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4180-5. Epub 2004 Mar 15.

Nolan D, Gaudieri S, Mallal S. Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity? J HIV Ther. 2003 May;8(2):36-41.

Additional Reference of Interest

Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV. The abacavir hypersensitivity reaction and interruptions in therapy. AIDS. 2001 Jul 6;15(10):1325-6.

Login

	Please log in and get access to thousands of resources about HIV disease and its treatment.
	Already a member?
	Username :
	Password :

	Lost your password?

Search our database

Find the information that you are looking for in over +3000 resources.

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR
BASED ON CONTENT FOUND HEREIN WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.